<?xml version="1.0" encoding="UTF-8"?>
<p id="p0155">Due to urgent need, we posit that drug repurposing is the leading method for drug discovery against COVID-19, whether through wet laboratory techniques and/or system biology approaches. Available clinical trials at both 
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0025" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" id="intref0030" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/</ext-link>) and WHO Solidarity includes the investigation of previously approved drugs for different indications. Taking into account that in the past two decades three coronaviruses emerged from animal reservoirs (the virus family that used to cause mild to moderate upper respiratory tract illnesses) and each one of them was cause of global concern, a common treatment may prevent coronavirus to become another lethal annual re-occurrent threat on top of seasonal influenza.
</p>
